Core Framework & Diagram Chronic Inflammation and Cancer
July 8, 20261 Min Read How Does the Tumor ‘Turn Off’ Immune Switches?
July 8, 2026There's a cancer risk you accumulate or spend down every day — it's called chronic inflammation burden
—— From H. pylori to obesity, from periodontal disease to sleep deprivation: which chronic inflammations genuinely push you toward cancer.
I. Grade A evidence: H. pylori — the clearest chronic inflammation → cancer causal chain
pylori's relationship with gastric cancer is the most evidence-complete, mechanism-clearest paradigm case in the chronic inflammation-cancer field. In 1994, WHO classified H. pylori as a Group I carcinogen. H. pylori's carcinogenic mechanism follows a predictable 'Correa Cascade' progression path: normal gastric mucosa → chronic active gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → gastric adenocarcinoma. Each step requires years to decades, with clear inflammation-driven mechanisms.
How much does H. pylori eradication reduce gastric cancer risk? A 2022 Lancet meta-analysis covering over 100,000 patients confirmed that H. pylori eradication therapy can reduce gastric cancer risk by approximately forty-six percent; and in populations without atrophic gastritis yet, gastric cancer incidence after eradication approaches that of uninfected populations. China has one of the world's highest H. pylori infection rates (approximately fifty to sixty percent) and is also the world's highest-incidence region for gastric cancer, with approximately 470,000 new cases annually — about forty-three percent of the global total. H. pylori screening and eradication treatment is one of China's most publicly significant cancer prevention interventions.
2. Grade A evidence: viral hepatitis — chronic infection 'grinding down' immune control
Chronic hepatitis from hepatitis B virus (HBV) and hepatitis C virus (HCV) are the world's most important hepatocellular carcinoma (HCC) causative factors, accounting for approximately eighty percent of global HCC cases. In chronic viral hepatitis, local T cell 'exhaustion' in the liver is the key link connecting chronic infection with immune control failure — CTLs are repeatedly activated, repeatedly defeated, ultimately entering exhaustion, unable to clear the virus or effectively monitor emerging cancerous cells.
HCV's 'miraculous' reversal: since 2014, direct-acting antivirals (DAAs) completely changed HCV treatment — over ninety-five percent of HCV patients achieve sustained virological response (SVR, functional cure) after eight to twelve weeks of oral treatment. After HCV cure, liver cancer risk drops significantly by approximately seventy to eighty percent; but in patients with already-existing cirrhosis, risk remains higher than ordinary people. This proves: 'clearing the infection = eliminating the inflammatory trigger,' but previously chronic inflammation's irreversible structural damage remains an independent cancer risk factor.
3. Grade A evidence: inflammatory bowel disease (IBD) — the gut's chronic fire ignites cancer
IBD patients (including UC and Crohn's disease) have colorectal cancer risk three to five times the general population. IBD-related colorectal cancer has several important features different from sporadic colorectal cancer: younger onset age (average twenty years earlier than sporadic); often multifocal (the entire colon under persistent inflammation is in a 'cancer-preparation' state); and relatively worse prognosis. IBD follows a different molecular pathway than sporadic colorectal cancer — 'chronic inflammation → epigenetic changes → chromosomal instability → cancer,' without passing through the adenoma stage. This is why ordinary colonoscopy 'looking for polyps' screening strategy doesn't fully apply to it; specialized chromoendoscopy is needed to find early flat-type lesions. Standardized IBD medication (especially 5-ASA drugs) has been proven to reduce IBD-related colorectal cancer risk by approximately fifty percent.
4. Grade B evidence: periodontal disease — a severely underestimated systemic cancer risk factor
The association between periodontal disease (chronic gum and alveolar bone infection) and cancer risk is one of the most surprising epidemiological findings of the past decade. A 2007 Harvard University prospective study covering 51,529 men found that those with a history of periodontal disease had fifty-four percent elevated pancreatic cancer risk; multiple subsequent studies confirmed this association, and it remained significant even in never-smokers (controlling for smoking confounding). Periodontal disease is associated with approximately thirty to fifty percent elevated risk of esophageal adenocarcinoma and squamous cell carcinoma.
The key mechanism: Fusobacterium nucleatum migrates via blood to the colon, colonizing colorectal cancer tissue in large numbers (the abundance of F. nucleatum in cancer tissue is approximately four hundred times that of normal mucosa). F. nucleatum through its surface protein FadA directly activates E-cadherin-Wnt signaling pathway, promoting colorectal cell proliferation and cancer; simultaneously suppressing local NK cell and T cell function, reducing tumor microenvironment immune surveillance efficiency. Periodontal disease is a highly controllable chronic inflammation source — professional cleaning at least once a year is a clearly evidenced systemic health investment.
5. Integrated strategy for reducing chronic inflammation burden
Priority one (Grade A evidence, act now): screen and eradicate H. pylori — especially those over forty with digestive discomfort, family history of gastric cancer, or from high-incidence regions; test and treat chronic viral hepatitis; standardized IBD treatment. Priority two (Grade B evidence, strongly recommended): control weight, especially abdominal obesity — five to ten percent weight loss has been proven to significantly lower multiple inflammatory markers; regular dental checkups and treating periodontal disease; quit smoking. Priority three (Grade C evidence, worth implementing): optimize sleep (seven to nine hours, regular schedule); Mediterranean dietary pattern; regular aerobic exercise; chronic stress management.
6. Correct interpretation of 'association': statistical risk isn't personal fate
When understanding the chronic inflammation-cancer association, there's a cognitive trap to avoid: equating group statistical risk with individual fate. 'H. pylori-infected people have three to six times elevated gastric cancer risk' means statistically, among one hundred infected people there would be a few more gastric cancer cases than among one hundred uninfected — but doesn't mean every infected person 'will definitely get gastric cancer.' Most infected people won't develop gastric cancer in their lifetime.
The correct attitude: acknowledge the real existence of statistical risk while not falling into panic or fatalism. The meaning of statistical risk lies in guiding 'where taking action is most valuable.' Understanding the evidence grade and actionability framework lets you transform knowledge about 'chronic inflammation and cancer' from anxiety into action.
7. Self-assessment of chronic inflammation burden: from understanding to action
A simple but practically valuable self-checklist: Have I been tested for H. pylori? (Those over forty, from East Asian regions, with digestive discomfort history — 'no' is a clear action signal.) Have I been tested for hepatitis B antibodies and hepatitis C antibody? (Most people need this only once in a lifetime.) When did I last see a dentist? (Over a year without professional cleaning — periodontal disease risk has already risen significantly.) Is my waist circumference within standard range? (Asian males over 90cm, females over 80cm — visceral fat inflammation risk signal.) Is my sleep regular, ensuring seven to nine hours nightly?
These five questions cover chronic inflammation's most important controllable sources, with corresponding interventions that are low-cost and high-benefit. hs-CRP (high-sensitivity C-reactive protein) is a comprehensive blood indicator for evaluating systemic chronic inflammation burden. If hs-CRP persistently exceeds 1 mg/L (after excluding acute infection and recent exercise), actively trace and treat chronic inflammation sources rather than simply watching the number.
Frequently Asked Questions